# DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

> **NCT06892678** · PHASE1,PHASE2 · RECRUITING · sponsor: **Montefiore Medical Center** · enrollment: 15 (estimated)

## Conditions studied

- Osteosarcoma Recurrent
- Ewing's Tumor Recurrent

## Interventions

- **DRUG:** DFMO

## Key facts

- **NCT ID:** NCT06892678
- **Lead sponsor:** Montefiore Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2030-04
- **Final completion:** 2030-04
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06892678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06892678, "DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT06892678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*